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The predicted impact of tuberculosis
preventive therapy: the importance of
disease progression assumptions
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Abstract
Background: Following infection with Mycobacterium tuberculosis (M.tb), individuals may rapidly develop tuberculosis
(TB) disease or enter a “latent” infection state with a low risk of progression to disease. Mathematical models use a
variety of structures and parameterisations to represent this process. The effect of these different assumptions on the
predicted impact of TB interventions has not been assessed.
Methods: We explored how the assumptions made about progression from infection to disease affect the predicted
impact of TB preventive therapy. We compared the predictions using three commonly used model structures, and
parameters derived from two different data sources.
Results: The predicted impact of preventive therapy depended on both the model structure and parameterisation. At
a baseline annual TB incidence of 500/100,000, there was a greater than 2.5-fold difference in the predicted reduction
in incidence due to preventive therapy (ranging from 6 to 16%), and the number needed to treat to avert one TB case
varied between 67 and 157. The relative importance of structure and parameters depended on baseline TB incidence
and assumptions about the efficacy of preventive therapy, with the choice of structure becoming more important at
higher incidence.
Conclusions: The assumptions use to represent progression to disease in models are likely to influence the predicted
impact of preventive therapy and other TB interventions. Modelling estimates of TB preventive therapy should consider
routinely incorporating structural uncertainty, particularly in higher burden settings. Not doing so may lead to
inaccurate and over confident conclusions, and sub-optimal evidence for decision making.
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Background
Tuberculosis (TB) is an infectious disease caused by the
bacteria Mycobacterium tuberculosis (M.tb). Following in-
fection with M.tb it is commonly stated that 10–15% of in-
dividuals will develop disease in their lifetime [1]. The risk
of developing TB is known to vary with time since infection,
with the highest risk in the first year following infection [2].
Disease may occur soon after infection or many years after
initial exposure, either through reactivation of “latent” infec-
tion or due to re-infection [3, 4]. The mechanisms that
underlie this process are incompletely understood.
Mathematical models are frequently used to predict the
impact of TB control strategies and to inform policy mak-
ing. These models use a variety of assumptions when
representing progression from infection with M.tb to TB
disease. Modellers must specify a model structure, the
states in the model and the relationships between them,
and the model parameters that determine the flows
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between these states. TB modelling studies often explore
the sensitivity of results to parameters (e.g. Sanchez and
Blower [5] and Dowdy and colleagues [6]), however the
majority of studies using models to predict the impact of
control strategies, while often including detailed features
such as age-structure, human immunodeficiency virus
(HIV) and TB treatment history, employ a single model
structure to describe the progression from infection to
disease (e.g. [7–13]). A number of studies have explored
the impact of model structure in the context of other in-
fectious diseases, including human papillomavirus [14]
and rota virus [15] but the importance of model structure
has not been widely studied in the context of TB.
Two recent papers [16, 17] compared the predictions of
different models for the progression from infection to dis-
ease when used to simulate cohorts of recently infected
people. The model predictions were compared to data on
the incidence of TB by time since M.tb infection from vari-
ous studies. These analyses showed that there is no single
“best” model and that several sets of assumptions are con-
sistent with the data. They also found that the assumptions
used in many published modelling studies are not consist-
ent with the observed temporal pattern of disease following
exposure to M.tb. The consequences of using these differ-
ent assumptions in transmission models used to simulate
TB control strategies remain unclear. In particular, do the
different “best” models give consistent results when used to
simulate interventions, and what are the implications of the
use of inconsistent model assumptions?
In this paper we explore how the assumptions (model
structure and parameters) used to represent progression
from infection to disease effect the predicted impact of a
scale up of TB preventive therapy. Preventive therapy
(treatment with one or more anti-tuberculosis drugs, typic-
ally for a period of 3 to 6months) reduces the risk of devel-
oping TB disease and is recommended by the World
Health Organisation (WHO) for high risk populations in-
cluding people living with HIV, household contacts of pul-
monary TB cases and dialysis and organ transplant patients
[18]. Previous modelling [11, 19, 20] has highlighted wider
use of preventive therapy as a key component of reaching
the WHO global TB targets [21]. As preventive therapy
aims to prevent progression from infection to disease, it is
important to understand how the assumptions used to rep-
resent this process may affect the model results.
Methods
We constructed a set of simple dynamic transmission
models to simulate the impact of increased uptake of TB
preventive therapy at different TB incidence. To explore
the effect of different assumptions about progression
from infection to disease we compared the predictions
made using 3 different model structures and parameter
estimates derived from 2 different data sets.
Model structures
Our choice of models was informed by a systematic lit-
erature review [17] that identified 12 model structures
that have been used to describe progression from infec-
tion to disease. A summary of all 12 model structures
can be found in the appendix.
Our primary analysis focuses on two structures (models
1 and 2) that have been shown to provide the best fit to
the observed incidence of TB by time since M.tb infection
in cohorts of recently exposed people [16, 17].
We also considered a third model structure (model 3)
that has been shown to provide a worse fit to the data [16,
17], but has been used in approximately 50% of published
modelling studies [17]. It was included here to explore the
implications of using an inappropriate structure on the
predicted impact of preventive therapy interventions.
Figure 1 shows the different model structures incorpo-
rated into a simple dynamic transmission model of TB.
The equations and steady state solutions for each of the
models are given in the appendix.
The following features are common to all models con-
sidered here. Susceptible individuals (S) are infected with
M.tb at a rate λ = βI where β is the rate of effective con-
tact and I is the prevalence of TB. Background mortality
is modelled at a constant rate, u, in all states. In
addition, those in the disease state, I, are subject to an
additional disease associated mortality rate, m. The birth
rate is set to maintain a constant population size. All
births are assumed to be susceptible. In all models we
assume that those with TB disease (I) are removed back
to the “slow” latent state (LS) at a rate, τ. This represents
effective treatment and natural recovery from disease.
Prior exposure to M.tb. is assumed to confer some im-
munity against re-infection. This is captured through the
parameter q which represents the relative susceptibility
to re-infection among those with “slow” latent infection
compared to the susceptibility to first infection among
previously uninfected individuals.
Model 1 consists of 2 sequential latent states. Following
infection all individuals enter the “fast” latent state (LF)
where they have an annual rate of progression to disease,
k. Those who do not develop disease transition to the
“slow” latent state (LS), at an annual rate, e, where they
have an annual rate of disease progression c (where c < k).
Biologically, this assumes that all infected individuals have
the same risk of developing TB following infection. Indi-
viduals in the “slow” latent state (LS) can be re-infected
and return to LF.
Model 2 consists of 2 parallel latent states. Following
infection, some proportion (b) enter the “fast” latent
state (LF) where they have an annual rate of progression
to disease, k. The remainder (1-b) enter the “slow” latent
state (LS) where they have an annual rate of disease pro-
gression c (where c < k). Biologically, this assumes that
Sumner and White BMC Infectious Diseases          (2020) 20:880 Page 2 of 8
Fig. 1 Schematic of model structures. S = susceptible; LF = “fast” latent state; LS = “slow” latent state; I = TB disease; PF = post preventive therapy
(from “fast” latent state); PS = post preventive therapy (from “slow” latent state). Red lines and boxes show the preventive therapy components of
the model. Definitions of model parameters are given in Table 1
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some proportion of individuals (b) are pre-determined
to have a high risk of developing TB following infection.
Individuals in LS can be re-infected with a proportion b
moving to LF and the remainder remaining in LS.
Model 3 consists of a single “slow” latent state, LS. Fol-
lowing infection, some proportion (a) develop disease im-
mediately. The remainder (1-a) enter the “slow” latent
state where they have an annual rate of disease progres-
sion c. This can be seen as equivalent to model 2 but with
an infinite rate of progression from the fast latent state to
disease. Individuals in LS can be re-infected with a propor-
tion a progressing directly to disease and the remainder
remaining in LS.
Model parameterisation
To explore the relative effects of parameter uncertainty
compared to structural uncertainty we used parameter
estimates for each model structure derived using 2 dif-
ferent data sets. Parameter set A is taken from Menzies
et al. [17] and based on data from individuals in the con-
trol arms of the British Medical Research Council’s Ba-
cillus Calmette–Guérin (BCG) vaccination trials [2] and
preventive therapy trials conducted by the United States
Public Health Service [22]. Parameter set B is taken from
Ragonnet et al. [16] and was obtained by fitting models
to data from recent cohorts in the Netherlands [23] and
Australia [24]. The parameter values are shown in
Table 1. These parameters result in different estimates
of the proportion of infected individuals who develop
disease over time (see figure A1 in the appendix).
For both parameter sets, models 1 and 2 predict the
same cumulative incidence over time while model 3 pre-
dicts a higher long-term risk of TB than the other
models (figure A1). Assuming a life expectancy of 50
years, models 1 and 2 predict a life-time risk of TB of
11% (using parameter set A) and 17% (parameter set B).
In contrast model 3 gives a life time risk of 20 and 21%
respectively.
Modelling the impact of preventive therapy
The aim of this analysis was not to make detailed predic-
tions of the impact of preventive therapy, rather to explore
how the predicted impact may vary due to the choice of
model structure and parameterisation. As such we use a
simple model of preventive therapy (shown in red in Fig. 1)
similar to that used previously to explore the relationship
between TB burden and preventive therapy impact [25].
For each model structure we assumed 5% of the popula-
tion in all latent states (θ = 0.05) is treated with preventive
therapy each year. Individuals receiving preventive therapy
in the “fast” and “slow” latent states move to correspond-
ing post preventive therapy states, PF and PS (note that in
model 3 there is only a single latent state and therefore
only a single preventive therapy state). We assume that
preventive therapy reduces the risk of disease from exist-
ing infection but does not prevent against re-infection.





a, proportion progressing directly to disease A – – 0.0665
B – – 0.085*
b, proportion entering fast latent state A – 0.086 –
B – 0.09 –
c, rate of progression to disease from slow latent state (per year) A 5.94 × 10−4 5.94 × 10− 4 3.37 × 10− 3
B 2.01 × 10− 3 2.01 × 10− 3 3.11 × 10− 3*
k, rate of progression to disease from fast latent state (per year) A 0.0826 0.955 –
B 0.4015 4.015 –
e, rate of movement from fast latent state to slow latent state (per year) A 0.872 – –
B 4.015 – –
q, relative susceptibility to re-infection compared to first infection 0.5 (To explore the role of re-infection in between model differences
we also simulated the model with no re-infection, q = 0)
τ, rate of recovery from TB disease (per year) 1 (assumes that the average duration of disease is approximately 1 year)
β, number of effective contacts (per year) Varied to produce different TB incidence
m, rate of TB associated mortality 0.03
w, relative risk of progressing to disease following preventive therapy 0.4 (In the primary analysis, we assume preventive therapy has an efficacy
of 60% against disease progression from prior infection. We explored the
impact of varying w on the results).
Parameter set A is taken form Menzies et al. [17], parameter set B is taken from Ragonnet et al. [16]. *These parameters are not reported in Ragonnet et al. [16] so
have been estimated by fitting the models to data extracted from figure S14 in [16] – full details are given in the appendix. Parameters in Ragonnet et al. [16] are
reported in daily units and have been converted to annual units. “-“indicates the parameter is not used in a given model
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This is incorporated in the model via the parameter w (see
Fig. 1). In our main analysis we assume a reduction of 60%
in the risk of progressing to disease [26] (i.e. w = 0.4) but
also explore the effect of assuming different values for w.
We simulated the introduction of preventive therapy
into a population in which TB was at an endemic steady
state (see appendix for steady state solutions for each
model) and explored a range of baseline TB incidence
from 0 to 1000/100,000 by varying the number of effect-
ive contacts per year (β). We calculated the percentage
reduction in TB incidence (compared to the endemic
equilibrium) after 10 years of preventive therapy. We
also calculated the cumulative number of cases averted,
the cumulative number of people given preventive ther-
apy and the average number needed to treat (NNT) with
preventive therapy to avert one TB case over the 10-year
period assuming a constant population of 10,000.
Results
Figure 2 shows the results of simulating 10 years of pre-
ventive therapy for each model structure as a function of
the steady state TB incidence assuming 5% annual cover-
age and a 60% efficacy of preventive therapy against pro-
gression to TB disease from prior infection. Colours show
the different model structures, solid lines show the results
using parameter set A and dashed lines the results using
parameter set B.
For all models, the reduction in TB incidence (left panel
of Fig. 2) declines as a function of increasing steady state
TB incidence; at higher incidence the risk of reinfection
after preventive therapy is greater which reduces the long-
term benefit of treatment. While the predicted impact de-
clines with increasing incidence, the absolute number of
cases averted increases with increasing steady state inci-
dence (not shown) because there are more cases which
can be prevented. The number of people treated with pre-
ventive therapy also increases with steady state incidence,
reflecting the higher prevalence of latent infection, how-
ever the NNT (right panel of Fig. 2) is found to decline
with increasing incidence. Previous analysis using a model
with structure 1 found a non-monotonic relationship be-
tween incidence and NNT [25]. In the appendix we show
that this behaviour is dependent on the assumed duration
of the fast latent state.
There is considerable difference between the predic-
tions using different model structures and parameter
sets. For example, at an incidence of 500/100,000, the
predicted reduction in incidence (left panel of Fig. 2)
ranges from 6 to 16%, a greater than 2.5-fold difference.
At the same incidence, the NNT (right panel of Fig. 2)
varies from 67 to 157. For each parameter set, model 2
predicts the lowest impact of preventive therapy while
model 3 predicts the highest impact. The larger impact
predicted by model 3 is due to the fact that this model
(as parameterised) results in a higher lifetime risk of
Fig. 2 Results of simulating 10 years of preventive therapy as a function of steady state TB incidence. Left: Percentage reduction in TB incidence
from steady state equilibrium. Right: average number needed to treat with preventive therapy to avert one case of TB. Colours indicate the
different models. Line types indicate the different sources of parameter estimates. Shaded areas illustrate the range of predictions for each model
across parameter sets
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developing TB following infection (see figure A1) and
therefore the contact rate (β) needed to produce a given
TB incidence is smaller (see figure A2). As a result, the
risk of reinfection (and therefore TB) after preventive
therapy is lower and the predicted impact of the inter-
vention is larger. If model 3 is re-parameterised to give
the same lifetime risk of TB as models 1 and 2 we ob-
served a lower impact from model 3. This is because it
is not possible to directly prevent fast progression to dis-
ease in this model structure by providing preventive
therapy to the latent populations; these cases do not pass
through a “fast” latent state where they can be treated
with preventive therapy (see appendix A5.). Model 2
gives the highest NNT and model 3 the lowest. In the
remainder of this section we focus on models 1 and 2.
The effects of assumptions about disease progression are
dependent on the TB incidence when preventive therapy is
introduced. Table 2 shows the overall range of results com-
pared to the ranges across structures (for a given parameter
set) and parameter sets (for a given structure). For a given
parameter set, the effect of the model structure on the pre-
dictions increases as the incidence of TB increases.
Figure 3 shows that, as expected, the impact of prevent-
ive therapy depends on the assumed efficacy of treatment,
but so do the interactions between the assumptions repre-
senting disease progression and the model outputs. In
particular, the choice between structure 1 or 2 appears to
be less influential if the assumed efficacy of preventive
therapy is higher.
Discussion
Our results show that both the model structure and par-
ameter values used to represent progression from infec-
tion to disease can affect model predictions of the impact
of preventive therapy on TB incidence and the number
needed to treat to prevent one case of TB. This highlights
the importance of including both structural and paramet-
ric uncertainty in TB modelling studies. Failure to do so
may result in inaccurate predictions of the potential im-
pact of interventions, and suboptimal evidence for deci-
sion making.
Our analysis extends the findings of two previous reviews
[16, 17]. Those analyses found that model structures 1 and
2 fit data on the cumulative incidence of TB following
infection equally well. In fact, it was shown in Ragonnet
et al. [16] that models 1 and 2 produce identical dynamics
of TB onset following infection. We show that despite this
these models can give markedly different predictions of
intervention impact and efficacy. We also find that model
3, which is commonly used but has been found to produce
a poor fit to the data, overestimates the impact (and under-
estimates the NNT) compared to models 1 and 2. This sug-
gests that models using structure 3 could result in
inappropriate recommendations for the use of preventive
therapy.
We found that the relative importance of the model
structure and the choice of parameters depends on the
baseline incidence, with the choice of structure becoming
more important at higher incidence This is due to the dif-
ferences in the risk of re-infection between the models
which become increasingly important at higher TB inci-
dence: in model 1 all individuals spend some time in the
“fast” latent state where they are not at risk of reinfection
in contrast to model 2 where only a fraction of individuals
pass through the fast latent state. The assumptions around
the efficacy of preventive therapy are also important both
in determining the overall impact and in the relative ef-
fects of model structure and parameterisation.
This work has focussed on the effect of assumptions
about progression from infection to disease on the impact
of preventive therapy. These assumptions may also affect
the predicted impact of other interventions. Other struc-
tural assumptions not considered here may also be im-
portant. Two previous studies have explicitly considered
the role of structural choices in TB modelling. As part of a
review of TB modelling Colijn et al. [27] explored how as-
sumptions around the mechanism of protection conferred
by prior immunity may affect model predictions. Fojo
et al. [28] compared the impact of a hypothetical case
finding intervention using three model structures. They
found that a model with a single latent state (our model 3)
predicted a lower impact than models with sequential high
and low risk states (our model 1). This is in agreement
with our findings that, in certain circumstances, model 3
can produce inconsistent results.
To allow us to explore a number of different assump-
tions for the progression from infection to latency the
rest of the model was kept as simple as possible. These





% of range due to structure % of range due to parameters
Parameters A Parameters B Model 1 Model 2
250 8.8–16.6 66% 10% 34% 90%
500 6.5–13.8 74% 16% 26% 84%
750 5.2–11.4 86% 23% 14% 77%
1000 4.5–9.6 98% 32% 2% 68%
Overall range of predicted reduction (due to both model choice and parameters) and the % of the range due to either choice of structure or choice of parameters
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simplifications may affect our findings. We did not con-
sider HIV or drug resistant forms of TB and we used a
very simple representation of demography, assuming a
constant population size and a constant life expectancy.
Previous work [29] has shown the importance of consid-
ering realistic age structure in models of TB transmis-
sion. The risks of developing disease have also been
shown to differ by age [23, 24, 30] and that simplified
models that do not include reactivation may be suitable
for modelling paediatric TB [16]. We also assumed TB
was in equilibrium before the introduction of preventive
therapy, but trends in disease may affect the prevalence
of infection and the contribution of ongoing transmis-
sion and reactivation to TB incidence. These factors are
likely to influence the model predictions of intervention
impact and may also affect the interaction between
structure, parameters and model outputs. The represen-
tation of the preventive therapy intervention was also
greatly simplified to explore the impact of model struc-
ture on the results and the findings should therefore not
be interpreted as predictions of the likely impact of pre-
ventive therapy in any specific setting.
To ensure both structural and parametric uncertainty
can be explored in a systematic way, standardised
methods for incorporating model structure are needed.
Approaches such as Bayesian model averaging [31] may
be of value for combining predictions from different
models, but more work is required to increase their use in
infectious disease modelling, in particular to address ap-
propriate methods of weighting different models [32, 33].
In addition to incorporating uncertainty in model pre-
dictions it is also important to quantify how different
sources of input uncertainty contribute to the variability
in outputs. Methods to conduct quantitative sensitivity
analysis [34] of both model structure and parameters are
needed. Approaches based on factorial sampling [35]
analysis of variance [36] or use of regression and classifi-
cation trees [37] could be utilised to quantify the im-
portance of model structure in TB modelling. Such
approaches would allow the key drivers of uncertainty to
be identified and focus efforts on collecting data which
will reduce uncertainty in future model predictions.
Conclusion
Uncertainty in model structure is often ignored in TB
modelling studies. Future studies should aim to compare
results using different structures to ensure the uncertainty
in model predictions is captured more accurately. When
differences exist in the predictions between models these
should be communicated to policy makers, either as
discrete scenarios or using more formal methods of model
averaging. Not doing so may lead to inaccurate and over
confident conclusions, and sub-optimal evidence for deci-
sion making.
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Fig. 3 Results of simulating 10 years of preventive therapy as a function of steady state TB incidence for different efficacy of preventive therapy.
Colours indicate the different models. Line types indicate the different sources of parameter estimates. Shaded areas illustrate the range of
predictions for each model across parameter sets
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